EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The calmodulin antagonist trifluoperazine in transient focal brain ischemia in rats. Anti-ischemic effect and therapeutic window



The calmodulin antagonist trifluoperazine in transient focal brain ischemia in rats. Anti-ischemic effect and therapeutic window



Stroke 28(12): 2539-2544



Background and purpose: This study was performed to assess the efficacy and the therapeutic window for the calmodulin antagonist trifluoperazine in experiments involving transient middle cerebral artery (MCA) occlusion. Methods: Male Wistar rats were subjected to transient (2 hours) MCA occlusion by an intraluminal filament technique. Trifluoperazine (5.0 mg cntdot kg-1) was injected intraperitoneally 5 minutes, 1 hour, or 2 hours after the induction of ischemia. Drug administration was repeated 24 hours after the first injection. Neurological scores and infarct volumes were evaluated at 48 hours of reperfusion. The effect of trifluoperazine on cortical blood flow was studied with continuous laser-Doppler flowmetry. Results: The median value of neurological scores in the control rats (n=7) was 3, while those in the treated groups were 1 (5-minute group; n=7, P<.05) and 2 (1-hour and 2-hour groups; each n=7). The percentage of infarct volume in the control rats was 34.8 +- 4.9% (mean+-SD), while those in the treated groups were 11.3+-12.3% (5-minute group; P<.01), 24.8+-15.1% (1-hour group), and 28.8+-8.3% (2-hour group). Trifluoperazine, given at 5 minutes after ischemia, had no influence on blood flow in the neocortical penumbra during and after ischemia. Conclusions: The results demonstrate that trifluoperazine markedly reduces infarct volume after 2 hours of MCA occlusion when given 5 minutes after the induction of ischemia. However, the therapeutic window for trifluoperazine seems narrow since the drug had no significant effect when given after 1 or 2 hours.

(PDF 0-2 workdays service: $29.90)

Accession: 009546674

Download citation: RISBibTeXText

PMID: 9412646



Related references

Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. Journal of Pharmacology and Experimental Therapeutics 294(1): 378-386, 2000

Therapeutic impact of eicosapentaenoic acid on ischemic brain damage following transient focal cerebral ischemia in rats. Brain Research 1519: 95-104, 2014

Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rat: therapeutic time window for FK506 in transient focal ischemia. Neurological Research 23(7): 755-760, 2001

Therapeutic window for use of hyperbaric oxygenation in focal transient ischemia in rats. Stroke 35(2): 578-583, 2004

Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window. Journal of Neurosurgery 85(6): 1108-1112, 1996

DY - 9760e, a novel calmodulin antagonist, reduces brain edema through the inhibition of enhanced blood - brain barrier permeability after transient focal ischemia. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 791 8, 2003

DY-9760e, a novel calmodulin antagonist, reduces brain damage induced by transient focal cerebral ischemia. European Journal of Pharmacology 370(2): 117-123, April 9, 1999

Therapeutic window for hypothermia after transient focal ischemia in spontaneously hypertensive rats. Stroke 29(1): 327, 1998

Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. Journal of Cerebral Blood Flow and Metabolism 16(1): 107-113, 1996

Therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury in rats. Neuroscience Letters 449(1): 24-27, 2008

Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats. Brain Research 1123(1): 60-67, 2006

Mild hypothermia enhances the neuroprotective effects of FK506 and expands its therapeutic window following transient focal ischemia in rats. Brain Research 1008(2): 179-185, 2004

Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia. Chinese Medical Journal 121(24): 2572-2577, 2009

3-(2-(4-(3-Chloro-2-methylphenyl)-1-piperazinyl)ethyl)-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, reduces brain edema through the inhibition of enhanced blood-brain barrier permeability after transient focal ischemia. Journal of Pharmacology and Experimental Therapeutics 304(3): 1042-1047, 2003